Thymalin Peptide
It has no sequence and no CAS number, because it is not a molecule. It is an extract of calf thymus, still in clinical use across Russia, and that combination is genuinely unusual.
Choose your pack
For research use only. Not for human or veterinary use.
What Thymalin Peptide is
The plain-language version, first.
Not a compound. A mixture, and the distinction changes everything downstream.
Thymalin is not a single peptide but a polypeptide extract prepared from calf thymus tissue, which means it is a mixture with no defined amino acid sequence and no single molecular weight. Because it is a mixture rather than a defined molecule it cannot be characterised the way a synthetic peptide can, and it has not been approved by the FDA, the EMA or Health Canada.
Every other entry on this shelf has a sequence. This one does not, and that is not an oversight in our data.
Thymalin is an extract. Calf thymus, fractionated, standardised by activity rather than by structure.
No sequence. No CAS number. No molecular weight.
There is nothing to put in those fields, because it is a mixture of peptides rather than one of them.
It came out of Soviet-era work on thymic bioregulators, and it did not stop there. It remains in clinical use in Russia today, which is a strange sentence to write about something Western regulators have never assessed.
Two medical traditions looked at the same material and reached completely different places. That is the actual story here.
What is thymalin?
Mechanism studied, not outcome promised.
Polypeptide fractions from calf thymus. No single sequence, no molar mass, no CAS number for one active substance, because there is not one.
You can test an extract as a whole, but you cannot say which component produced an effect or establish a dose-response for it.
You cannot write a clean mechanism for something with no defined composition.
Here's why the mechanism section on this page is going to disappoint you, and why that is the correct outcome.
To describe a mechanism you need to know what the thing is. A mixture standardised by activity can vary batch to batch in composition while still meeting its specification.
Which means any mechanism you write is a mechanism for an average, not for what is in the vial.
That is not unique or disgraceful. Plenty of legitimate biological products are extracts. But it does put a ceiling on how precisely anybody can talk.
The proposed activity concerns thymic peptides and immune signalling, which is a real field with real molecules in it.
Here's the honest part. Anybody giving you a crisp receptor-level account of this material is describing something more defined than what exists.
We would rather say the composition is not fully specified than pretend a precision nobody has.
The research so far for Thymalin Peptide
Where the evidence is thin, we say so.
Decades of clinical use in Russia and the former Soviet states, a Russian-language literature in immune deficiency and gerontology, and some long-term observational work.
A defined chemical identity. Placebo-controlled trials in any quantity. Independent replication outside the originating system. Approval by the FDA, EMA or Health Canada.
For most compounds you know what is in the vial and are uncertain about what it does, or the reverse. Thymalin has both open: an undefined composition and a regional clinical literature that is largely uncontrolled and unreplicated outside its originating system. That combination is worth naming plainly.
A large clinical literature in one country, largely unread outside it.
This one has more clinical literature than most of the shelf and almost none of it is in English.
Decades of Russian clinical work exists, in a system with its own standards, its own journals and its own regulatory framework.
Dismissing it because it is unfamiliar would be lazy. Treating it as equivalent to a Western phase 3 would be wrong.
What is genuinely missing is independent replication under the methodological conventions most readers here would expect, and translation that makes the primary work accessible.
No Health Canada or FDA assessment. Nothing approved in North America.
A substantial file in one tradition, essentially unexamined in another, and a mixture rather than a molecule underneath both. All three of those are worth knowing before you weigh any of it.
Have a look at the vial sizes we keep in stock.
Thymalin Peptide specs
The chemistry, exactly as released.
Who studies Thymalin Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Immunology
T cell maturation and differentiation, and whether thymic secretions can be usefully supplemented as the gland involutes.
Gerontology
Thymic involution is one of the better documented features of ageing immunity, and some of the Russian long-term work sits here.
Analytical chemistry
Characterising a tissue extract is a genuinely hard problem, and it is the reason any purity number means something narrower here.
Nobody, in Western trials
We could not identify a registered clinical trial of Thymalin with any Western regulator. That is the honest answer for this row.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Thymalin Peptide backstory
How it got here.
Working out what the thymus secretes took decades of fractionating animal thymus tissue and testing the fractions. Thymosin fraction 5 was one of the crude preparations from that effort in the West, and thymosin alpha-1 was eventually isolated and characterised out of it.
Soviet research followed a parallel track with its own preparations, and Thymalin came out of that. It remained an extract rather than being resolved into a defined molecule, and it entered clinical use in that form.
That is the fork in the road worth understanding. One tradition kept purifying until it had a single peptide it could synthesise, name and register internationally.
The other put the extract into practice. Thymalin is the second path, and it is why the compound has clinical history but no sequence.
- 1
The gland that shrinks
The thymus trains T cells and involutes steadily from adolescence. Replacing what it stops secreting drove decades of work on thymic preparations.
- 2
Two traditions diverge
Western work fractionated until it had a defined peptide it could synthesise and register. Soviet work put the extract itself into clinical practice.
- 3
Thymalin is the second path
It entered use as a mixture and stayed one, which is why it has clinical history and no sequence.
Buying Thymalin Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
This one is not a defined peptide
It is a calf thymus extract. Any purity number on a tissue extract answers a narrower question than the same number on a defined molecule, and we would rather say that plainly than let a figure imply more than it can.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Once it lands, fridge. That is the whole ask.
Do not confuse it with thymosin alpha-1
Thymosin alpha-1 is a defined 28 residue peptide approved as a drug in more than thirty countries. Thymalin is an undefined extract approved by no Western regulator. They share a source organ and nothing else that matters.
Thymalin Peptide vs Thymosin Alpha-1
Stacked together constantly, compared almost never.
Both came out of the great thymus gold rush, and the difference between them is the difference between a molecule and a mixture.
Thymalin is an extract: calf thymus, fractionated, standardised by activity. No sequence, no CAS number, batch-variable by nature. Its clinical record is substantial and almost entirely Russian.
Thymosin alpha-1 is a defined 28-residue peptide, licensed as Zadaxin in more than thirty countries, with a real if geographically split regulatory record.
If the question is which thymus product the wider world has actually examined, it is not close. The defined molecule travelled. The extract stayed home. Thymosin Alpha-1 has its own page here
Stuff people ask about Thymalin Peptide
If your question is not here, email us. Real human answers.
Not in the sense most products here are. It is an extract prepared from calf thymus glands, a mixture of polypeptide fractions rather than a single characterised molecule. There is no published amino acid sequence, no molar mass and no CAS number for one active substance, because there is not one.
Substantially. Thymosin alpha-1 is a defined 28 amino acid peptide, made synthetically, with an international nonproprietary name and approval as a drug in more than thirty countries. Thymalin is an undefined tissue extract used regionally and approved by no Western regulator. They share a source organ and very little else.
It has been used clinically in Russia and the former Soviet states for decades. It has never been approved by the FDA, the EMA or Health Canada, and we could not identify any registered Western clinical trial of it.
Not in a way that means much, and we would rather be straight about that. On a single molecule, purity establishes that the vial contains that molecule and little else. On a tissue extract it describes a narrower property. Same number, different job.
Regional and largely uncontrolled. There is a Russian-language clinical literature in immune deficiency states and gerontology, including some long-term observational work. Placebo control is frequently absent, the reporting predates modern trial standards, and very little has been independently replicated outside the originating system.
Because it is a biological extract rather than a synthesised molecule. The output depends on the source tissue and the extraction process rather than a defined synthesis route, so lot-to-lot variation is inherent to the material rather than a manufacturing failure.
Good pairing options with Thymalin Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Thymalin Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Without a zinc atom it is completely inert. Not less active. Inert. The metal is not a supporting player here, it is half the molecule's identity.
The alpha-MSH analogue that grew up and got approved as SCENESSE for a rare light-sensitivity disorder. The approved product is a subdermal implant in a clinic. This is not that, and the difference is the page.
Order Thymalin Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Thymalin Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Thymalin Peptide
Other names for the same compound.